$2.8 B

BOLD Mkt cap, 15-Jan-2020
Audentes Therapeutics Net income (Q3, 2019)-45.7 M
Audentes Therapeutics EBIT (Q3, 2019)-47.8 M
Audentes Therapeutics Cash, 30-Sept-201963.6 M
Audentes Therapeutics EV2.7 B

Audentes Therapeutics Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018

R&D expense

48.8m75.9m104.4m

General and administrative expense

11.3m17.3m30.0m

Operating expense total

60.0m93.2m134.4m

EBIT

(60.0m)(93.2m)(134.4m)

Interest income

472.0k

Investment income

767.0k6.0m

Pre tax profit

(59.7m)(92.5m)(128.8m)

Income tax expense

(2.2m)

Net Income

(59.7m)(90.2m)(128.8m)

Audentes Therapeutics Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018

Cash

36.4m39.0m144.3m

Prepaid Expenses

2.8m3.3m5.5m

Current Assets

108.4m137.0m419.8m

PP&E

18.9m24.4m32.1m

Goodwill

3.6m3.6m3.6m

Total Assets

142.1m178.7m472.6m

Accounts Payable

2.4m3.9m8.1m

Current Liabilities

12.6m17.7m23.9m

Total Liabilities

22.7m22.1m29.8m

Common Stock

29.9m43.5m

Additional Paid-in Capital

219.8m347.3m762.3m

Retained Earnings

(100.4m)(190.6m)(319.5m)

Total Equity

119.4m156.6m442.8m

Financial Leverage

1.2 x1.1 x1.1 x

Audentes Therapeutics Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018

Net Income

(59.7m)(90.2m)(128.8m)

Depreciation and Amortization

1.6m3.4m5.6m

Accounts Payable

(671.0k)686.0k4.1m

Cash From Operating Activities

(49.0m)(84.5m)(108.0m)

Purchases of PP&E

(16.7m)(7.6m)(11.6m)

Cash From Investing Activities

(62.0m)(33.4m)(185.0m)

Dividends Paid

Cash From Financing Activities

75.4m120.6m398.5m

Net Change in Cash

(35.7m)2.6m105.4m

Audentes Therapeutics Ratios

USDQ2, 2016

Financial Leverage

1.3 x

Audentes Therapeutics Employee Rating

321 votes
Culture & Values
3
Work/Life Balance
3
Senior Management
2.7
Salary & Benefits
4.3
Career Opportunities
3.3
Source